safety test in luteolin

JRCT ID: jRCTs041210142

Registered date:14/02/2022

Basic Information

• Recruitment status: Complete
• Health condition(s) or Problem(s) studied: prostate cancer patients
• Date of first enrollment: 14/02/2022
• Target sample size: 5
• Study type: Interventional
• Intervention(s): Orally taking luteolin 50mg for 24 weeks

Outcome(s)

• Primary Outcome: incidence and severity in adverse events
• Secondary Outcome: PSA or UA response from baseline

Key inclusion & exclusion criteria

• Age minimum: >= 20age old
• Age maximum: Not applicable
• Gender: Male

Include criteria

1)newly diagnosed, or recurrence after radical treatment but slowly progression in PSA in low risk patients
2)initial PSA < 10ng/mL, and cT2, orrecurrence after radical treatment but slowly progressed 0.05ng/mL per year in PSA
3)patients with informed consent in this research
4) male patients older than 20
5)patients with less than ECOG PS 1

Exclude criteria

patients in dementia
patients with severe infection
patients with hepatic dysfunction
patients with renal disorders
patients who was recognized as inadequate in this test by doctors

Related Information

• Primary Sponsor: Naiki-Ito Aya